238 related articles for article (PubMed ID: 24839254)
1. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.
Kitamura T; Srivastava J; DiGiovanni J; Kiguchi K
Mol Carcinog; 2015 Jun; 54(6):459-72. PubMed ID: 24839254
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Kiguchi K; Ruffino L; Kawamoto T; Ajiki T; Digiovanni J
Clin Cancer Res; 2005 Aug; 11(15):5572-80. PubMed ID: 16061875
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
5. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion.
Xian W; Rosenberg MP; DiGiovanni J
Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
8. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors.
Cheng K; Raufman JP
Biochem Pharmacol; 2005 Oct; 70(7):1035-47. PubMed ID: 16139803
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Kitamura T; Connolly K; Ruffino L; Ajiki T; Lueckgen A; DiGiovanni J; Kiguchi K
J Hepatol; 2012 Jul; 57(1):84-91. PubMed ID: 22326466
[TBL] [Abstract][Full Text] [Related]
10. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
11. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition.
Kiesslich T; Alinger B; Wolkersdörfer GW; Ocker M; Neureiter D; Berr F
Int J Oncol; 2010 Jan; 36(1):49-58. PubMed ID: 19956832
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma.
Ojima H
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):319-25. PubMed ID: 22278347
[TBL] [Abstract][Full Text] [Related]
13. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
16. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol.
Miyagawa S; Katsu Y; Watanabe H; Iguchi T
Oncogene; 2004 Jan; 23(2):340-9. PubMed ID: 14647453
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
20. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
